NEWRON PHARMACEUT. EO-20 (NP5) — Net Asset Momentum
NEWRON PHARMACEUT. EO-20 (NP5) recorded a net asset momentum of -863.7% as of December 2025, with net assets of €-11.13 Million EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See NEWRON PHARMACEUT. EO-20 (NP5) defensive interval to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
NEWRON PHARMACEUT. EO-20 Net Asset Momentum (2021–2025)
This chart tracks NEWRON PHARMACEUT. EO-20's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is -863.7%, with net assets of €-11.13 Million EUR as of December 2025. Read NEWRON PHARMACEUT. EO-20 (NP5) financial obligations for a breakdown of total debt and financial obligations.
Annual Net Asset History for NEWRON PHARMACEUT. EO-20 (2021–2025)
The table below shows the complete annual net asset history for NEWRON PHARMACEUT. EO-20 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see NP5 company net worth.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €-11.13 Million | €40.05 Million | €51.19 Million | ▼ -863.7% |
| 2024 | €1.46 Million | €63.91 Million | €62.45 Million | ▲ +104.9% |
| 2023 | €-29.91 Million | €25.87 Million | €55.77 Million | ▼ -113.2% |
| 2022 | €-14.03 Million | €37.20 Million | €51.23 Million | ▼ -551.6% |
| 2021 | €3.11 Million | €50.49 Million | €47.38 Million | — |